Naquotinib
- Generic Name
- Naquotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H42N8O3
- CAS Number
- 1448232-80-1
- Unique Ingredient Identifier
- 47DD4548PB
- Background
Naquotinib has been used in trials studying the treatment of Solid Tumors, Non-small Cell Lung Cancer, Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations, and Epidermal Growth Factor Receptor (EGFR) Mutations, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
- Conditions
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03082300
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸Renovatio Clinical, The Woodlands, Texas, United States
🇺🇸US Oncology - Virginia Cancer Specialists, P.C. (VCS), Fairfax, Virginia, United States
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT02674555
A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02113813
- Locations
- 🇺🇸
Site US10008, New York, New York, United States
🇺🇸Site US10010, Washington, District of Columbia, United States
🇺🇸Site US10006, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.